- Clinical Trials
- April 2024
- 40 Pages
Global
From €1189EUR$1,250USD£999GBP
- Report
- June 2024
- 200 Pages
Global
From €7559EUR$7,950USD£6,356GBP
- Report
- May 2024
- 129 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- January 2022
- 60 Pages
Global
From €3756EUR$3,950USD£3,158GBP
- Report
- May 2022
- 36 Pages
Global
From €1902EUR$2,000USD£1,599GBP
Erosive Esophagitis (EE) is a type of Gastrointestinal (GI) disorder that is caused by the inflammation of the esophagus due to acid reflux. EE is a common disorder, and is often treated with medications such as proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs). These medications are used to reduce the amount of acid produced in the stomach, and to reduce the symptoms of EE.
The EE drug market is a subset of the larger GI drug market, and is composed of a variety of medications used to treat EE. These medications are available in both prescription and over-the-counter forms, and are used to reduce the symptoms of EE and to prevent further damage to the esophagus.
The EE drug market is highly competitive, with many companies offering a variety of medications to treat EE. Some of the major companies in the EE drug market include AstraZeneca, Pfizer, GlaxoSmithKline, Merck, and Novartis. Show Less Read more